Frontlight ResearchEarly access
Myelodysplastic syndromes trials in France
41 of 50 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in FranceBexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
- Where
- Paris, Pessac, Poitiers, Villejuif
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Faron Pharmaceuticals Ltd
See details and how to joinNCT07672769 · EU 2026-526706-33-00 - Phase 3Taking peopleStudy comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome and receiving an allogeneic stem cell transplantation with an unrelated matched donor after a reduced intensity conditioning regimen
- Where
- Amiens Cedex 1, Angers, Besancon Cedex, Brest Cedex 2, Caen Cedex 9, Clermont-Ferrand, Creteil Cedex, Grenoble Cedex 9, Lille, Limoges, Marseille, Montpellier Cedex 5, Nantes, Nice, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy, Villejuif
- Age
- 18 years and over
- People
- 334 worldwide
- Run by
- Assistance Publique Hopitaux De Paris
See details and how to join2023-504555-27-00 - Phase 1Not yet taking people in FranceBioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
- Where
- Lille, Pessac, Pierre-Bénite, Villejuif
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT07929740 · EU 2025-524332-19-00 - Phase 1Taking peopleA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Marseille, Pierre-Bénite, Toulouse, Tours
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 - Phase 3Taking peopleA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Where
- Nice, Paris, Poitiers, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 225 worldwide
- Run by
- Takeda
See details and how to joinNCT06499285 · EU 2024-516009-22-00 - Phase 3Not yet taking people in FranceA Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
- Where
- Grenoble Cedex 9, Nice, Paris, Poitiers, Villejuif
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00 - Phase 1Taking peopleA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Lille, Marseille, Nantes, Paris, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 1Taking peopleStudy of REM-422 in Patients With AML or Higher Risk MDS
- Where
- Bordeaux, Paris, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Remix Therapeutics
See details and how to joinNCT06297941 - No phaseTaking peopleInvolvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
- Where
- Marseille
- Age
- 18 years and over
- People
- 70
- Run by
- Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06886425 - Phase 2Taking peopleMomelotinib in VEXAS syndrome
- Where
- Angers, Clermont-Ferrand, Grenoble Cedex 9, Lille, Lorient, Nantes, Paris, Paris Cedex 12, Pessac, Pierre-Bénite, Rennes Cedex 9, Toulouse, Tours Cedex 9
- Age
- 18 years and over
- People
- 57
- Run by
- Groupe Francophone Des Myelodysplasies
See details and how to join2024-519779-24-00 - Phase 2Taking peopleA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Where
- Nantes, Nice, Paris, Pessac, Pontoise
- Age
- 18 years and over
- People
- 210 worldwide
- Run by
- Takeda
See details and how to joinNCT04419649 · EU 2023-507469-24-00 - Phase 2Active, not recruitingA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
- Where
- Lille, Paris, Pierre-Bénite, Poitiers, Toulouse
- Age
- 18 years and over
- People
- 156 worldwide
- Run by
- Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00 - Phase 1CompletedPhase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Where
- Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- Auron Therapeutics, Inc.
See details and how to joinNCT06846606 · EU 2025-521394-13-00 - Phase 3Taking peopleLisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- Where
- Angers, Le Mans Cedex 9, Limoges, Nantes, Nantes Cedex 2, Nice, Orleans Cedex 2, Paris, Pessac, Poitiers, Pontoise, Tours Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00 - No phaseTaking peopleFeasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
- Where
- Oullins-Pierre-Bénite
- Age
- 18 years and over
- People
- 13
- Run by
- Hospices Civils de Lyon
See details and how to joinNCT06781099 - Phase 2/3Taking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- Nice, Paris, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - Phase 4Taking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- ANGERS Cedex 09, Grenoble Cedex 09, Nantes, Pessac, Rennes Cedex 9, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 - No phaseTaking peopleStudy for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation
- Where
- Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Rennes, Rouen, Saint-Priest-en-Jarez, Sèvres, Strasbourg, Toulouse, Tours, Vandœuvre-lès-Nancy
- People
- 150
- Run by
- Institut Claudius Regaud
See details and how to joinNCT05983991 - Phase 1/2Taking peopleStudy Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
- Where
- Amiens, Amiens Cedex 1, Angers, Argenteuil Cedex, Avignon, Bayonne, Bobigny, Cesson Sevigne, Compiegne, Grenoble Cedex 9, Le Chesnay Rocquencourt, Le Kremlin Bicetre Cedex, Le Mans Cedex 9, Lille Cedex, Limoges, Mont-De-Marsan Cedex, Montpellier Cedex 5, Nantes, Nantes Cedex 2, Nice, Nimes Cedex 9, Orleans Cedex 2, Paris, Périgueux, Pessac, Pierre-Bénite, Poitiers, Pontoise, Quimper Cedex, Rennes, Rouen, Saint-Priest-en-Jarez, Strasbourg, Toulouse Cedex 9, Tours, Valence, Vandoeuvre Les Nancy
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Groupe Francophone des Myelodysplasies
See details and how to joinNCT05181735 · EU 2024-515354-24-00 - Phase 2Taking peopleFaecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
- Where
- Amiens, Angers, Besançon, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon, Nancy, Nantes, Nice, Paris, Pessac, Poitiers, Rouen, Saint-Etienne, Toulouse
- Age
- 18 years and over
- People
- 150
- Run by
- University Hospital, Clermont-Ferrand
See details and how to joinNCT04935684 - Phase 2Taking peopleRVU120 Rollover Study
- Where
- Nice, Pessac
- Age
- 18 years and over
- People
- 14 worldwide
- Run by
- Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00 - Phase 2Active, not recruiting(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Paris, Poitiers, Toulouse
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 1/2Taking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- Lille Cedex, Nice, Paris
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - Phase 1Taking peopleOral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
- Where
- Nice, Paris, Villejuif
- Age
- 18 years and over
- People
- 24
- Run by
- Groupe Francophone des Myelodysplasies
See details and how to joinNCT06670222 · EU 2024-515311-22-00 - Phase 3Taking peopleIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Where
- Nantes, Nice, Paris, Pessac, Toulouse Cedex 9, Vandoeuvre Les Nancy Cedex
- Age
- 18 years and over
- People
- 48 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT06465953 · EU 2023-510155-37-00